Show simple item record

dc.contributor.authorRobbins, Hilary A.
dc.contributor.authorFerreiro-Iglesias, Aida
dc.contributor.authorWaterboer, Tim
dc.contributor.authorBrenner, Nicole
dc.contributor.authorNygård, Mari
dc.contributor.authorBender, Noemi
dc.contributor.authorSchroeder, Lea
dc.contributor.authorHildesheim, Allan
dc.contributor.authorPawlita, Michael
dc.contributor.authorD'Souza, Gypsyamber
dc.contributor.authorVisvanathan, Kala
dc.contributor.authorLangseth, Hilde
dc.contributor.authorSchlecht, Nicolas F.
dc.contributor.authorTinker, Lesley F.
dc.contributor.authorAgalliu, Ilir
dc.contributor.authorWassertheil-Smoller, Sylvia
dc.contributor.authorNess-Jensen, Eivind
dc.contributor.authorHveem, Kristian
dc.contributor.authorGrioni, Sara
dc.contributor.authorKaaks, Rudolf
dc.contributor.authorSánchez, Maria-Jose
dc.contributor.authorWeiderpass, Elisabete
dc.contributor.authorGiles, Graham G.
dc.contributor.authorMilne, Roger L.
dc.contributor.authorCai, Qiuyin
dc.contributor.authorBlot, William J.
dc.contributor.authorZheng, Wei
dc.contributor.authorWeinstein, Stephanie J.
dc.contributor.authorAlbanes, Demetrius
dc.contributor.authorHuang, Wen-Yi
dc.contributor.authorFreedman, Neal D.
dc.contributor.authorKreimer, Aimée R
dc.contributor.authorJohansson, Mattias
dc.contributor.authorBrennan, Paul
dc.date.accessioned2023-05-15T13:18:16Z
dc.date.available2023-05-15T13:18:16Z
dc.date.created2022-11-15T14:29:41Z
dc.date.issued2022
dc.identifier.citationJournal of Clinical Oncology. 2022, 40 (31), 3613-3622.en_US
dc.identifier.issn0732-183X
dc.identifier.urihttps://hdl.handle.net/11250/3067972
dc.description.abstractPURPOSE Seropositivity for the HPV16-E6 oncoprotein is a promising marker for early detection of oropharyngeal cancer (OPC), but the absolute risk of OPC after a positive or negative test is unknown. METHODS We constructed an OPC risk prediction model that integrates (1) relative odds of OPC for HPV16-E6 serostatus and cigarette smoking from the human papillomavirus (HPV) Cancer Cohort Consortium (HPVC3), (2) US population risk factor data from the National Health Interview Survey, and (3) US sex-specific population rates of OPC and mortality. RESULTS The nine HPVC3 cohorts included 365 participants with OPC with up to 10 years between blood draw and diagnosis and 5,794 controls. The estimated 10-year OPC risk for HPV16-E6 seropositive males at age 50 years was 17.4% (95% CI, 12.4 to 28.6) and at age 60 years was 27.1% (95% CI, 19.2 to 45.4). Corresponding 5-year risk estimates were 7.3% and 14.4%, respectively. For HPV16-E6 seropositive females, 10-year risk estimates were 3.6% (95% CI, 2.5 to 5.9) at age 50 years and 5.5% (95% CI, 3.8 to 9.2) at age 60 years and 5-year risk estimates were 1.5% and 2.7%, respectively. Over 30 years, after a seropositive result at age 50 years, an estimated 49.9% of males and 13.3% of females would develop OPC. By contrast, 10-year risks among HPV16-E6 seronegative people were very low, ranging from 0.01% to 0.25% depending on age, sex, and smoking status. CONCLUSION We estimate that a substantial proportion of HPV16-E6 seropositive individuals will develop OPC, with 10-year risks of 17%-27% for males and 4%-6% for females age 50-60 years in the United States. This high level of risk may warrant periodic, minimally invasive surveillance after a positive HPV16-E6 serology test, particularly for males in high-incidence regions. However, an appropriate clinical protocol for surveillance remains to be established.en_US
dc.language.isoengen_US
dc.publisherAmerican Society of Clinical Oncologyen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleAbsolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortiumen_US
dc.title.alternativeAbsolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortiumen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber3613-3622en_US
dc.source.volume40en_US
dc.source.journalJournal of Clinical Oncologyen_US
dc.source.issue31en_US
dc.identifier.doi10.1200/JCO.21.01785
dc.identifier.cristin2074368
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal